FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,24 +0,51 (+0,62%) Bitcoin EUR
60.718,64 +567,10 (+0,94%)
Microbot Medical Inc. (MBOT)
Dopo ore:
| Chiusura precedente | 0,8900 |
| Aperto | 0,8875 |
| Denaro | 0,8323 x 100 |
| Lettera | 0,8954 x 100 |
| Min-Max giorno | 0,8618 - 0,8875 |
| Intervallo di 52 settimane | 0,8600 - 4,3700 |
| Volume | |
| Media Volume | 100.374 |
| Capitalizzazione | 12,455M |
| Beta (5 anni mensile) | 1,65 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,0500 |
| Prossima data utili | 15 mag 2024 - 20 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 7,00 |
GlobeNewswireMicrobot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial
The engagement is an additional step in the Company's path towards marketing clearance with the FDABRAINTREE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, announced today its partnership with a Contract Research Organization (CRO) in the U.S. This is an additional step in the preparations to the commencement of the Company's planned upcoming clinical trial.
- GlobeNewswire
Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023
The presentation follows successful extensive uses of the Company’s endovascular robotic system in pre-clinical studiesBRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023. The abstract is to be present
- GlobeNewswire
Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System
The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials followed by regulatory approval and commercializationBRAINTREE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, announces another step in its commitment to advance the commercialization processes of LIBERTY® with th
